Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab two monoclonal antibody treatments under Food and Drug Administration emergency use authorization keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine. Nearly 1,400 Mayo Clinic patients were [...]

The post Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19 appeared first on Outbreak News Today.